Big Tech’s New Obsession Is AI Drug Discovery, Zuckerberg Is Latest To Join In
Meta CEO Mark Zuckerberg and his wife Dr. Priscilla Chan’s research organization, Biohub, launched an AI model focused on protein biology to accelerate drug discovery, joining a trend led by tech leaders like Sam Altman. The model, based on Evolutionary Scale Modelling (ESM), aims to predict protein behavior and speed up research in cancer and immune diseases while being open-source for broader use.
Meta CEO Mark Zuckerberg and his wife Dr. Priscilla Chan’s research organization, Biohub, have launched an AI-powered drug discovery initiative focused on protein biology. The project leverages the latest version of Evolutionary Scale Modelling (ESM), which analyzes protein sequences shaped by evolution over millions of years. This approach aims to predict protein behavior, reducing the time and cost of lab testing for potential treatments. The model has already been tested in cancer and immune disease research, with Dr. Chan stating it could help researchers progress faster on existing projects. Biohub has committed to making the AI tools open-source, allowing external researchers to access and utilize them without restrictions. Zuckerberg is not the only tech leader investing in AI-driven biotech. Sam Altman, CEO of OpenAI, has aggressively backed companies like Retro Biosciences, which focuses on extending human lifespan through experimental treatments for diseases such as Alzheimer’s. Altman reportedly provided $180 million in funding to the startup. As major tech figures invest in AI for drug discovery, the industry is shifting away from traditional pharmaceutical research toward an AI-focused competition. The collaboration between Meta and Biohub marks another step in this evolving landscape, where technology and biotechnology intersect to accelerate medical advancements.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.